Compounds of formula (I), wherein R1 to R8 A, B, Z1 and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17a-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
公式(I)的化合物,其中R1至R8,A,B,Z1和Z2如权利要求中所定义,并且其药用盐和
酯被披露。公式(I)的化合物具有作为雄激素受体
拮抗剂(
抑制剂)和/或细胞色素P450单加
氧酶17a-羟化酶/17,20-裂解酶(CYP17)
抑制剂的效用。这些化合物在治疗癌症,特别是前列腺癌,以及其他需要雄激素拮抗作用的疾病和情况中作为药物是有用的。